

## **CardioGenics featured on cover of Medical Device & Diagnostic Industry magazine**

*Article by CEO Dr. Yahia Gawad Addresses Improvements in Diagnostic Times Using Point-of-Care Technology*

MISSISSAUGA, ON – October 6, 2010 – Dr. Yahia Gawad, CEO of CardioGenics Inc. (OTCBB: CGNH), has authored a cover story for this month's *Medical Device & Diagnostic Industry Magazine* (MD+DI) which addresses improvements in diagnostic times using point-of-care technology. In the article, titled "*Improving Diagnosis Times with New Point-of-Care Technology*," Dr. Gawad reviews the in-vitro diagnostics market and the growth of point-of-care testing.

In addition to reviewing other point-of-care devices, Dr. Gawad describes the operation of the QL Care Analyzer™, CardioGenics' point-of-care immunoassay platform that will allow a heart attack diagnosis to be made in as little as 15 minutes vs. the national average of 2.8 hours required for test results from a central lab. CardioGenics expects to submit to the FDA a 510K application for the QL Care Analyzer™ (and its first cardiac test, Troponin-I) during Q1 2011 and to have both commercialized by Q2 2011.

The article can be accessed online at:

<http://www.mddionline.com/article/improving-diagnosis-times-new-point-care-technology>

*About Medical Device & Diagnostics Industry*

*Medical Device & Diagnostic Industry* is a leading monthly magazine written exclusively for original equipment manufacturers of medical devices and in vitro diagnostic products. The goal of *MD&DI* is to help industry professionals develop, design, and manufacture medical products that comply with complex and demanding regulations and market requirements. *MD&DI* is published 12 times each year, along with two additional issues of its *Guide to Outsourcing* supplement.

*About CardioGenics Holdings Inc.*

Through its operating subsidiaries, the Company develops ultra-sensitive analyzers and other products targeting the immunoassay segment of the Point-Of-Care IVD testing market. It has developed the QL Care™ Analyzer, a proprietary and ultra-sensitive Point-Of-Care immuno-analyzer, which will run a number of diagnostic tests under development, the first of which will be a series of cardiovascular diagnostic tests. As part of its core proprietary technology, the Company has also developed a proprietary method for silver coating paramagnetic microspheres (a fundamental platform component of

immunoassay equipment), which improve instrument sensitivity to light. The Company's principal offices are located in Mississauga, Ontario, Canada. For more information please visit [www.cardiogenics.com](http://www.cardiogenics.com).

*Safe Harbor Statement - Certain statements made herein that are not historical are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995 and may contain forward-looking statements, with words such as "Anticipate," "believe," "expect," "future," "may," "will," "should," "plan," "projected," "intend," and similar expressions to identify forward-looking statements. These statements are based on the Company's beliefs and the assumptions it made using information currently available to it. Because these statements reflect the Company's current views concerning future events, these statements involve risks, uncertainties and assumptions. The actual results could differ materially from the results discussed in the forward-looking statements. In any event, undue reliance should not be placed on any forward-looking statements, which apply only as of the date of this press release. Accordingly, reference should be made to the Company's periodic filings with the Securities and Exchange Commission.*

SOURCE CardioGenics Holdings Inc.

**Contacts:**

**Investor Relations:**

Redington Inc.  
CardioGenics Desk  
Tel: 203.222.7399